Clinical Trial Update: Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients [Phase 3]

View source ↗

Summary

Phase 3 study of Ivonescimab for first-line treatment of metastatic non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Summit Therapeutics | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING